Gefitinib
| Code | Size | Price |
|---|
| SYN-1042-M100 | 100 mg | Enquire |
Quantity:
| SYN-1042-M001 | 1 mg | £57.00 |
Quantity:
| SYN-1042-M005 | 5 mg | £74.00 |
Quantity:
| SYN-1042-M010 | 10 mg | £86.00 |
Quantity:
| SYN-1042-M050 | 50 mg | £151.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
-20°C
Documents
Further Information
Alternate Names/Synonyms:
ZD1839; Iressa
Appearance:
Solid.
CAS:
184475-35-2
EClass:
32160000
Form (Short):
liquid
GHS Symbol:
GHS07,GHS08,GHS09
Hazards:
H302 H315, H319, H351, H361, H373, H401, H411
InChi:
InChI=1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27)
InChiKey:
XGALLCVXEZPNRQ-UHFFFAOYSA-N
Long Description:
Chemical. CAS: 184475-35-2. Formula: C22H24ClFN4O3. MW: 446.9. Gefitinib is a selective, orally available epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. In NR6wtEGFR and NR6W cells, it inhibits Tyr1173, Tyr992, Tyr1173 and Tyr992 with IC(50) values of 37nM, 37nM, 26nM and 57nM, respectively.
Molecular Formula:
C22H24ClFN4O3
Molecular Weight:
446.9
Package Type:
Plastic Vial
Precautions:
P264, P270, P301, P312, P330, P501, P280, P302, P352, P321, P332, P313, P362, P305, P351, P338, P337, P313P, P201, P202, P281, P308, P313, P405, P260, P314, P273, P391
Product Description:
Gefitinib is a selective, orally available epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. In NR6wtEGFR and NR6W cells, it inhibits Tyr1173, Tyr992, Tyr1173 and Tyr992 with IC(50) values of 37nM, 37nM, 26nM and 57nM, respectively.
Purity:
>95%
Signal word:
Warning
Solubility Chemicals:
Soluble in DMSO or ethanol.
Transportation:
Non-hazardous
UNSPSC Category:
Protein Kinase Modulators
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C.
References
ZD1839 ('Iressa') as an anticancer agent: J. Baselga & S.D. Averbuch; Drugs 60, 33 (2000) | Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor: F. Ciardiello, et al.; Clin. Cancer Res. 6, 2053 (2000) | Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor: D. McKillop, et al.; Mol. Cancer Ther. 4, 641 (2005)
Related Products
| Product Name | Product Code | Supplier | Genistein | AG-CN2-0427 | AdipoGen Life Sciences | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|